Arctic Bioscience As · OSL:ABS
Arctic Bioscience As — Investor Presentation (March 2021)
24 slides from Arctic Bioscience As's investor presentation, March 2021
Slide 1: Arctic Bioscience Company Presentation
Arctic Bioscience Company Presentation March 2021 1
Slide 2: Company highlights
Company highlights Key value proposition 11 Significant unmet medical need in mild-to-moderate psoriasis - USD 20bn+ market for moderate psoriasis alone 22 Strong scientific rationale and promising clinical effect in mild-to-moderate psoriasis1,2 33 Cash generating and growing nutraceutical business
Slide 3: Two unique businesses built on a single proprietary platform
Arctic Bioscience Two unique businesses shaped built on a single proprietary platform technology platform 12 weeks 18 weeks 26 weeks Large unmet medical need for efficacious, non-invasive treatment option in mild to moderate psoriasis. Developing novel oral treatment (drug candidate HRO350) for mild
Slide 4: Founding story
Founding story Arctic Bioscience was founded based on unique knowledge and know-how about the benefits of herring roe Key lessons learned through nutra product enables efficient development of the pharma product 2017-2020: Building the foundation framework for a robust clinical program 2017 2019 202
Slide 5: Proprietary technology platform with control over value chain
Proprietary technology platform with control over value chain Sustainable competitive advantage ensured through vertical integration of the value chain Arctic Bioscience’s comprehensive value chain Sustainable raw material + State-of-the-art manufacturing Herring capture By-product: Immature roe Ext
Slide 6: Exciting pharma opportunity in mild to moderate psoriasis
Exciting pharma opportunity in mild to moderate psoriasis
Slide 7: Targeting large patient population with mild-to-moderate psoriasis
Targeting large patient population with mild -to-moderate psoriasis WHO has called for new, safe, and effective medications1 Country Incidence rate Prevalence rate Prevalent pool (mill) ▪ ~24 million people in EU & US have psoriasis 0.07% 3.2% 10.5 ▪ ~3% prevalence rate 0.14% 2.8% 1.9 ▪ Worldwide ma
Slide 8: Unique pharma opportunity in mild-to-moderate psoriasis
Unique pharma opportunity in mild -to-moderate psoriasis EMA CHMP also supportive Randomized, double-blind placebo controlled clinical trial showed statistically significant improvement in mild to moderate psoriasis compared to placebo Clinical trial in 64 patients with mild to moderate psoriasis (P
Slide 9: Greatest efficacy seen in subjects with moderate psoriasis
Greatest efficacy seen in subjects with moderate psoriasis Statistically significant improvement in PASI versus placebo Subgroup analysis | Subjects with PASI baseline>5.5 ▪ Randomized, placebo-controlled pilot clinical trial in mild to moderate psoriasis (PASI<10, n=64) PASI score HRO Placebo (swit
Slide 10: Efficacy is sustained and increases over time
Efficacy is sustained and increases over time Supported by secondary variable (PSGA) at week 65 (n=58) Relative change in PSGA score from baseline Improvement in disease severity % of subjects % of subjects 100% 100% ▪ All patients had PSGA scores ≥2 and 90% 90% ≤4 at inclusion 80% 80% ▪ 40% of pati
Slide 11: Natural product with compelling safety profile
Natural product with compelling safety profile Based on unique know-how throughout proprietary production process, protected by strong IP Safety profile | Well tolerated in pilot clinical trial Natural product | Extract from herring roe ✓ Demonstrated efficacy from pilot clinical study ✓ First-in-cl
Slide 12: Open market opportunity for safe and effective oral treatment
Open market opportunity for safe and effective oral treatment Clear need for new therapies targeting the moderate psoriasis segment Mild Moderate Severe HRO350 scores well against competitors (PASI<3) (PASI>3) (PASI>10) ✓ Administration Oral Oral BIOSCIENCE ✓ Active substance No other product with a
Slide 13: Key Opinion Leaders see significant unmet medical need
Key Opinion Leaders see significant unmet medical need Few treatment options for mild to moderate psoriasis 50-300k NOK per year (Europe & USA) Very expensive, limited to severe patients “ The biggest unmet need is that of an oral therapy that is totally safe Biologics (PASI>10) and contraindicated
Slide 14: Large Phase IIb study to drive pharma forward
Large Phase IIb study to drive pharma forward Initiating phase IIb trial to investigate efficacy, safety and dose of drug candidate HRO350 versus placebo Phase IIb study design ▪ Initiating large randomized Phase IIb study in 1Q 2022 in patients with mild-to-moderate psoriasis Patients: 519 ▪ Given
Slide 15: USD 20bn+ market opportunity in moderate psoriasis alone
USD 20bn+ market opportunity in moderate psoriasis alone (USA + EU5) USD 1bn+ per year revenue opportunity in moderate psoriasis with further substantial revenue upside in mild psoriasis Total Addressable Market in USA and EU5 Moderate psoriasis offer an addressable market opportunity of USD 20 bn+
Slide 16: Cash generating nutraceutical business with clear growth strategy
Cash generating nutraceutical business with clear growth strategy
Slide 17: Nutraceutical business
Nutraceutical business Romega | Premium Omega-3 products extracted, produced and distributed directly to consumers and in bulk (B2B) Key highlights Financials Historical Nutra Geographical growth Cash generating and business with loyal and growing customer base focus sales (NOKm) Vast global omega-3
Slide 18: Successful launch in China through Kotler partnership
Successful launch in China through Kotler partnership Partnership with Kotler serves as precedent for Arctic Bioscience’s go-to-market strategy going forward • Massive market – Several billion dollar Omega-3 market with strong growth expected due to rising middle-class population coupled with strong
Slide 19: Nutraceutical business longer-term ambitions
Nutraceutical business longer-term ambitions Metric Outlook and Strategy ▪ Fastest growth expected in high margin finished product categories (both B2C and B2B) and protein High % revenue growth ▪ Strategic sales and marketing partnerships in APAC and USA represent efficient routes to market Sharp i
Slide 20: Both businesses underpinned by proprietary technology and strong management team
Both businesses underpinned by proprietary technology and strong management team
Slide 21: State of the art manufacturing facility
State of the art manufacturing facility Vertical integration throughout the value chain seals sustainable competitive advantage ▪ Investing in growth through a new state-of-the-art manufacturing facility with GMP standard ▪ Secures full control of value chain from proprietary know-how and IP through
Slide 22: Strong management team
Strong management team Broad experience within the pharmaceutical and nutraceutical industries Management team with top expertise and experience Ole Arne Eiksund, MSc, MBA Danielle Glenn, BA Runhild Gammelsæter, PhD Hogne Hallaråker, MSc CEO CFO Global Medical Director CSO +30 years experience +20 y
Slide 23: Investment highlights
Investment highlights Key value proposition Significant unmet medical need in psoriasis • Large target market with 21m patients across EU and the US in 20191 11 represents USD 20bn+ market for moderate • Few and poor treatment options and a patient population with a high degree of disease-involvemen
Slide 24: FO Nar
FO Nar Vv BIOSCIENCE vw
Arctic Bioscience — Investor Presentation (March 2021) on 6ix